Maximilian Diehn

List of Publications by Year
in descending order

224 papers	36,737 citations	12303 69 h-index	3714 179 g-index
230 all docs	230 docs citations	230 times ranked	47518 citing authors

#	Article	IF	Citations
1	Predictive Radiation Oncology â€" A New NCIâ€"DOE Scientific Space and Community. Radiation Research, 2022, 197, .	0.7	4
2	Detection of Recurrence After Thoracic Stereotactic Ablative Radiotherapy Using FDG-PET-CT. Clinical Lung Cancer, 2022, 23, 282-289.	1.1	1
3	Inferring gene expression from cell-free DNA fragmentation profiles. Nature Biotechnology, 2022, 40, 585-597.	9.4	63
4	Acute and Late Esophageal Toxicity After SABR to Thoracic Tumors Near or Abutting the Esophagus. International Journal of Radiation Oncology Biology Physics, 2022, 112, 1144-1153.	0.4	2
5	Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA. Cancers, 2022, 14, 2479.	1.7	3
6	Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer. Cancer Research, 2022, 82, 2838-2847.	0.4	14
7	Detection and Diagnostic Utilization of Cellular and Cell-Free Tumor DNA. Annual Review of Pathology: Mechanisms of Disease, 2021, 16, 199-222.	9.6	16
8	Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC. Journal of Thoracic Oncology, 2021, 16, 395-403.	0.5	33
9	A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study. Oncologist, 2021, 26, 523-532.	1.9	4
10	Global analysis of shared TÂcell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. Immunity, 2021, 54, 586-602.e8.	6.6	80
11	Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response <i>In Vivo</i>. Cancer Discovery, 2021, 11, 1736-1753.	7.7	59
12	Phased variants improve DLBCL minimal residual disease detection at the end of therapy.. Journal of Clinical Oncology, 2021, 39, 7565-7565.	0.8	1
13	Leveraging phased variants for personalized minimal residual disease detection in localized non-small cell lung cancer.. Journal of Clinical Oncology, 2021, 39, 8518-8518.	0.8	4
14	Noninvasive identification of emergent mutations following cytotoxic therapy for lung cancer.. Journal of Clinical Oncology, 2021, 39, 8533-8533.	0.8	1
15	Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. Journal of Thoracic Oncology, 2021, 16, 1030-1041.	0.5	79
16	Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nature Biotechnology, 2021, 39, 1537-1547.	9.4	151
17	Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2021, 39, 2605-2616.	0.8	37
18	Radiological tumour classification across imaging modality and histology. Nature Machine Intelligence, 2021, 3, 787-798.	8.3	41

#	Article	IF	Citations
19	A Comprehensive Circulating Tumor DNA Assay for Detection of Translocation and Copy-Number Changes in Pediatric Sarcomas. Molecular Cancer Therapeutics, 2021, 20, 2016-2025.	1.9	15
20	The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. Cancer Cell, 2021, 39, 1422-1437.e10.	7.7	102
21	Atlas of clinically distinct cell states and ecosystems across human solid tumors. Cell, 2021, 184, 5482-5496.e28.	13.5	116
22	Targeted Treatment of Multiple Primary Lung Cancers Harboring Distinct EGFR or RET Alterations: A Case Report. Clinical Lung Cancer, 2021, 22, e673-e677.	1.1	2
23	Local Recurrence Outcomes of Colorectal Cancer Oligometastases Treated With Stereotactic Ablative Radiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 559-564.	0.6	6
24	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. Journal of Thoracic Oncology, 2021, 16, 1647-1662.	0.5	274
25	Tumor-Confirmed Follicular Lymphoma Mutations Are Detectable in Peripheral Blood Years Prior to Clinical Diagnosis. Blood, 2021, 138, 709-709.	0.6	1
26	Profiling of Circulating Tumor DNA for Noninvasive Disease Detection, Risk Stratification, and MRD Monitoring in Patients with CNS Lymphoma. Blood, 2021, 138, 6-6.	0.6	15
27	Noninvasive Cell-of-Origin Classification of Diffuse Large B-Cell Lymphoma Using Inferred Gene Expression from Cell-Free DNA Sequencing. Blood, 2021, 138, 37-37.	0.6	0
28	Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease. Cancer Discovery, 2021, 11, 2968-2986.	7.7	116
29	Stem Cells, Cell Differentiation, and Cancer. , 2020, , 97-107.e5.		2
30	Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer. Gastroenterology, 2020, 158, 494-505.e6.	0.6	147
31	Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non–Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 274-281.	3.2	75
32	<i>KEAP1/NFE2L2</i> Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition. Cancer Discovery, 2020, 10, 1826-1841.	7.7	93
33	Early response evaluation using primary tumor and nodal imaging features to predict progression-free survival of locally advanced non-small cell lung cancer. Theranostics, 2020, 10, 11707-11718.	4.6	32
34	Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. Cell, 2020, 183, 363-376.e13.	13.5	206
35	Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma. Clinical Cancer Research, 2020, 26, 6176-6186.	3.2	13
36	Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy. Nature Communications, 2020, 11, 6410.	5.8	66

#	Article	IF	Citations
37	A mathematical model of ctDNA shedding predicts tumor detection size. Science Advances, 2020, 6, .	4.7	105
38	A human lung tumor microenvironment interactome identifies clinically relevant cell-type cross-talk. Genome Biology, 2020, 21, 107.	3.8	33
39	Lack of supporting data make the risks of a clinical trial of radiation therapy as a treatment for COVID-19 pneumonia unacceptable. Radiotherapy and Oncology, 2020, 147, 217-220.	0.3	49
40	Response Letter: Radiation therapy for COVID-19 pneumopathy. Radiotherapy and Oncology, 2020, 149, 238-239.	0.3	3
41	Integrating genomic features for non-invasive early lung cancer detection. Nature, 2020, 580, 245-251.	13.7	379
42	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper. Nature Reviews Clinical Oncology, 2020, 17, 757-770.	12.5	218
43	Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. Nature Cancer, 2020, 1, 176-183.	5.7	201
44	Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer. JAMA Oncology, 2020, 6, 650.	3.4	696
45	Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. Clinical Cancer Research, 2020, 26, 2849-2858.	3.2	74
46	Mechanisms and Markers of Clinical Radioresistance. Cancer Drug Discovery and Development, 2020, , 63-96.	0.2	1
47	Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA). Blood, 2020, 136, 49-50.	0.6	3
48	Recurrent Crebbp Mutations in Follicular Lymphoma Appear Localized to the Committed B-Cell Lineage. Blood, 2020, 136, 30-31.	0.6	2
49	Predictors of Respiratory Decline Following Stereotactic Ablative Radiotherapy to Multiple Lung Tumors. Clinical Lung Cancer, 2019, 20, 461-468.e2.	1.1	5
50	Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. Cell, 2019, 178, 699-713.e19.	13.5	138
51	Stereotactic ablative radiotherapy for central and ultra-central lung tumors. Therapeutic Radiology and Oncology, 2019, 3, 18-18.	0.2	3
52	Predicting HLA class II antigen presentation through integrated deep learning. Nature Biotechnology, 2019, 37, 1332-1343.	9.4	218
53	FLT-PET-CT for the Detection of Disease Recurrence After Stereotactic Ablative Radiotherapy or Hyperfractionation for Thoracic Malignancy: A Prospective Pilot Study. Frontiers in Oncology, 2019, 9, 467.	1.3	8
54	Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer. Lung Cancer, 2019, 134, 42-45.	0.9	37

#	Article	IF	Citations
55	Increases in Serial Pretreatment 18F-FDG PET-CT Metrics Predict Survival in Early Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiation Therapy. Advances in Radiation Oncology, 2019, 4, 429-437.	0.6	2
56	Determining cell type abundance and expression from bulk tissues with digital cytometry. Nature Biotechnology, 2019, 37, 773-782.	9.4	2,396
57	Reply to J. Wang et al. Journal of Clinical Oncology, 2019, 37, 755-757.	0.8	2
58	SABR-COMET: harbinger of a new cancer treatment paradigm. Lancet, The, 2019, 393, 2013-2014.	6.3	14
59	Deep segmentation networks predict survival of non-small cell lung cancer. Scientific Reports, 2019, 9, 17286.	1.6	59
60	Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib. Anti-Cancer Drugs, 2019, 30, 537-541.	0.7	41
61	Functional significance of U2AF1 S34F mutations in lung adenocarcinomas. Nature Communications, 2019, 10, 5712.	5.8	27
62	Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA. Cancer Discovery, 2019, 9, 500-509.	7.7	143
63	A Feasibility Study of Single-inhalation, Single-energy Xenon-enhanced CT for High-resolution Imaging of Regional Lung Ventilation in Humans. Academic Radiology, 2019, 26, 38-49.	1.3	2
64	Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy. Blood, 2019, 134, 550-550.	0.6	13
65	An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma. Blood, 2019, 134, 655-655.	0.6	4
66	Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA. Blood, 2019, 134, 552-552.	0.6	5
67	Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL. Blood, 2019, 134, 1600-1600.	0.6	3
68	Towards Non-Invasive Classification of DLBCL Genetic Subtypes By Ctdna Profiling. Blood, 2019, 134, 551-551.	0.6	9
69	Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma. Blood, 2019, 134, 491-491.	0.6	0
70	Deep Sequencing of Viral Cell-Free DNA for Noninvasive Detection of Immunosuppression-Related Lymphoid Malignancies. Blood, 2019, 134, 885-885.	0.6	0
71	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Archives of Pathology and Laboratory Medicine, 2018, 142, 1242-1253.	1.2	120
72	Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma. Clinical Cancer Research, 2018, 24, 2688-2699.	3.2	45

#	Article	IF	Citations
73	18F-EF5 PET-based Imageable Hypoxia Predicts Local Recurrence in Tumors Treated With Highly Conformal Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1183-1192.	0.4	22
74	Genomic feature selection by coverage design optimization. Journal of Applied Statistics, 2018, 45, 2658-2676.	0.6	1
75	Endothelial deletion of Ino80 disrupts coronary angiogenesis and causes congenital heart disease. Nature Communications, 2018, 9, 368.	5.8	71
76	A Quantitative CT Imaging Signature Predicts Survival and Complements Established Prognosticators in Stage I Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1098-1106.	0.4	20
77	Circulating tumor DNA testing in advanced non-small cell lung cancer. Lung Cancer, 2018, 119, 42-47.	0.9	31
78	Deactivated CRISPR Associated Protein 9 for Minor-Allele Enrichment in Cell-Free DNA. Clinical Chemistry, 2018, 64, 307-316.	1.5	30
79	Prognostic value and molecular correlates of a CT image-based quantitative pleural contact index in early stage NSCLC. European Radiology, 2018, 28, 736-746.	2.3	17
80	Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non–Small-Cell Lung Cancer in the United States and Vietnam. Journal of Global Oncology, 2018, 4, 1-9.	0.5	3
81	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Journal of Clinical Oncology, 2018, 36, 1631-1641.	0.8	668
82	Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2018, 36, 2845-2853.	0.8	313
83	Line-Enhanced Deformable Registration of Pulmonary Computed Tomography Images Before and After Radiation Therapy With Radiation-Induced Fibrosis. Technology in Cancer Research and Treatment, 2018, 17, 153303461774941.	0.8	2
84	*GFPT2*-Expressing Cancer-Associated Fibroblasts Mediate Metabolic Reprogramming in Human Lung Adenocarcinoma. Cancer Research, 2018, 78, 3445-3457.	0.4	75
85	(OA02) Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 101, e1-e2.	0.4	0
86	Invasive nodal evaluation prior to stereotactic ablative radiation for non-small cell lung cancer. Lung Cancer, 2018, 124, 76-85.	0.9	2
87	Distinct Chromatin Accessibility Profiles of Lymphoma Subtypes Revealed By Targeted Cell Free DNA Profiling. Blood, 2018, 132, 672-672.	0.6	4
88	Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing. Blood, 2018, 132, 2861-2861.	0.6	0
89	Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma. Blood, 2018, 132, 2838-2838.	0.6	1
90	ERBB2 -Mutated Metastatic Non–Small Cell Lung Cancer: Response and Resistance to Targeted Therapies. Journal of Thoracic Oncology, 2017, 12, 833-842.	0.5	86

#	Article	IF	Citations
91	Pulmonary function after lung tumor stereotactic ablative radiotherapy depends on regional ventilation within irradiated lung. Radiotherapy and Oncology, 2017, 123, 270-275.	0.3	6
92	Sinoatrial node toxicity after stereotactic ablative radiation therapy to lung tumors. Practical Radiation Oncology, 2017, 7, e525-e529.	1.1	9
93	High-throughput sequencing for noninvasive disease detection in hematologic malignancies. Blood, 2017, 130, 440-452.	0.6	66
94	A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer. Lung Cancer, 2017, 108, 173-182.	0.9	11
95	Normal Tissue Constraints for Abdominal and Thoracic Stereotactic Body Radiotherapy. Seminars in Radiation Oncology, 2017, 27, 197-208.	1.0	68
96	MA17.07 Circulating Tumor DNA Detects Minimal Residual Disease and Predicts Outcome in Localized Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S445.	0.5	1
97	Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer. Radiotherapy and Oncology, 2017, 125, 338-343.	0.3	29
98	Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discovery, 2017, 7, 1394-1403.	7.7	701
99	Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nature Genetics, 2017, 49, 1693-1704.	9.4	423
100	Randomized Phase II Study of Preoperative Chemoradiotherapy Â± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Nonâ€"Small Cell Lung Cancer: NRG Oncology RTOG 0839. Journal of Thoracic Oncology, 2017, 12, 1413-1420.	0.5	22
101	Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Nonâ€"Small Cell Lung Cancer. JAMA Oncology, 2017, 3, 1529.	3.4	412
102	A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE). BMC Cancer, 2017, 17, 453.	1.1	83
103	Practical workflow for rapid prototyping of radiation therapy positioning devices. Practical Radiation Oncology, 2017, 7, 442-445.	1.1	2
104	Role of *KEAP1*/*NRF2* and *TP53* Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance. Cancer Discovery, 2017, 7, 86-101.	7.7	239
105	Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA. Journal of Oncology, 2017, 2017, 1-5.	0.6	20
106	Data normalization considerations for digital tumor dissection. Genome Biology, 2017, 18, 128.	3.8	25
107	Comprehensive Analysis of the Unfolded Protein Response in Breast Cancer Subtypes. JCO Precision Oncology, 2017, 2017, 1-9.	1.5	6
108	Early prediction of clinical outcomes in resected stage II and III colorectal cancer (CRC) through deep sequencing of circulating tumor DNA (ctDNA).. Journal of Clinical Oncology, 2017, 35, 3591-3591.	0.8	27

#	Article	IF	Citations
109	Sinoatrial node dysfunction after stereotactic ablative radiation therapy in the chest.. Journal of Clinical Oncology, 2017, 35, 132-132.	0.8	0
110	A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE).. Journal of Clinical Oncology, 2017, 35, TPS5094-TPS5094.	0.8	0
111	Development of a Dynamic Model for Personalized Risk Assessment in Large B-Cell Lymphoma. Blood, 2017, 130, 826-826.	0.6	4
112	Hypofractionated Intensity-Modulated Radiotherapy for Patients With Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2016, 17, 588-594.	1.1	19
113	Molecular profiling of single circulating tumor cells from lung cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E8379-E8386.	3.3	90
114	Reprogramming the immunological microenvironment through radiation and targeting Axl. Nature Communications, 2016, 7, 13898.	5.8	150
115	PS01.67: Case Series of MET Exon 14 Skipping Mutation-Positive Non–Small Cell Lung Cancers and Response to Crizotinib. Journal of Thoracic Oncology, 2016, 11, S312-S313.	0.5	1
116	Noninvasive Cancer Classification Using Diverse Genomic Features in Circulating Tumor DNA. , 2016, , .		0
117	Robust Intratumor Partitioning to Identify High-Risk Subregions in Lung Cancer: A Pilot Study. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1504-1512.	0.4	71
118	Early-Stage Non–Small Cell Lung Cancer: Quantitative Imaging Characteristics of ^{18}F Fluorodeoxyglucose PET/CT Allow Prediction of Distant Metastasis. Radiology, 2016, 281, 270-278.	3.6	152
119	A 3-D Riesz-Covariance Texture Model for Prediction of Nodule Recurrence in Lung CT. IEEE Transactions on Medical Imaging, 2016, 35, 2620-2630.	5.4	31
120	The impact of audiovisual biofeedback on 4D functional and anatomic imaging: Results of a lung cancer pilot study. Radiotherapy and Oncology, 2016, 120, 267-272.	0.3	10
121	Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Science Translational Medicine, 2016, 8, 364ra155.	5.8	348
122	Control of inflammation by stromal Hedgehog pathway activation restrains colitis. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7545-E7553.	3.3	73
123	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nature Communications, 2016, 7, 11815.	5.8	520
124	Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR). Radiotherapy and Oncology, 2016, 119, 454-460.	0.3	27
125	Time course and predictive factors for lung volume reduction following stereotactic ablative radiotherapy (SABR) of lung tumors. Radiation Oncology, 2016, 11, 40.	1.2	5
126	Integrated digital error suppression for improved detection of circulating tumor DNA. Nature Biotechnology, 2016, 34, 547-555.	9.4	837

#	Article	IF	Citations
127	Dosimetric Factors and Toxicity in Highly Conformal Thoracic Reirradiation. International Journal of Radiation Oncology Biology Physics, 2016, 94, 808-815.	0.4	31
128	Long-Term Survival of a Patient With Non–Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene. Clinical Lung Cancer, 2016, 17, e17-e21.	1.1	11
129	Identification and genetic manipulation of human and mouse oesophageal stem cells. Gut, 2016, 65, 1077-1086.	6.1	27
130	Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 1089-1089.	0.6	8
131	Noninvasive Detection of Ibrutinib Resistance in Non-Hodgkin Lymphoma Using Cell-Free DNA. Blood, 2016, 128, 1752-1752.	0.6	8
132	Prediction of therapeutic outcomes in DLBCL from circulating tumor DNA dynamics.. Journal of Clinical Oncology, 2016, 34, 7511-7511.	0.8	3
133	Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib.. Journal of Clinical Oncology, 2016, 34, 9000-9000.	0.8	2
134	Integrated digital error suppression for noninvasive detection of circulating tumor DNA in NSCLC.. Journal of Clinical Oncology, 2016, 34, e20500-e20500.	0.8	1
135	Noninvasive molecular subtyping and risk stratification of DLBCL.. Journal of Clinical Oncology, 2016, 34, 7554-7554.	0.8	2
136	Randomized phase II study of preoperative chemoradiotherapy (CRT)+/- Panitumumab (P) followed by consolidation chemotherapy (C) in potentially operable locally advanced (stage IIIa, N2+) non-small cell lung cancer (LANSCLC): Nrg oncology/RTOG 0839.. Journal of Clinical Oncology, 2016, 34, 8510-8510.	0.8	0
137	Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 2930-2930.	0.6	8
138	Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations. Blood, 2016, 128, 4107-4107.	0.6	1
139	Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors. Lung Cancer, 2015, 89, 50-56.	0.9	151
140	Deep sequencing of circulating tumor DNA for personalized cancer detection and monitoring. Annals of Oncology, 2015, 26, vii3.	0.6	0
141	Outcomes of Modestly Hypofractionated Radiation for Lung Tumors: Pre- and Mid-Treatment Positron Emission Tomography-Computed Tomography Metrics as Prognostic Factors. Clinical Lung Cancer, 2015, 16, 475-485.	1.1	9
142	Analysis of Long-Term 4-Dimensional Computed Tomography Regional Ventilation After Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 92, 683-690.	0.4	17
143	Noninvasive pulmonary nodule elastometry by CT and deformable image registration. Radiotherapy and Oncology, 2015, 115, 35-40.	0.3	7
144	Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA. Seminars in Radiation Oncology, 2015, 25, 305-312.	1.0	97

#	Article	IF	Citations
145	The prognostic landscape of genes and infiltrating immune cells across human cancers. Nature Medicine, 2015, 21, 938-945.	15.2	2,505
146	Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq. Expert Review of Molecular Diagnostics, 2015, 15, 715-719.	1.5	75
147	Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood, 2015, 125, 3679-3687.	0.6	270
148	Colorectal Histology Is Associated With an Increased Risk of Local Failure in Lung Metastases Treated With Stereotactic Ablative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 92, 1044-1052.	0.4	61
149	Inhibition of Mouse Breast Tumor-Initiating Cells by Calcitriol and Dietary Vitamin D. Molecular Cancer Therapeutics, 2015, 14, 1951-1961.	1.9	56
150	Robust enumeration of cell subsets from tissue expression profiles. Nature Methods, 2015, 12, 453-457.	9.0	8,460
151	Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial. International Journal of Radiation Oncology Biology Physics, 2015, 93, 72-81.	0.4	62
152	Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non–Small Cell Lung Cancer. Journal of the National Cancer Institute, 2015, 107, djv211.	3.0	64
153	Anatomic optimization of lung tumor stereotactic ablative radiation therapy. Practical Radiation Oncology, 2015, 5, e607-e613.	1.1	4
154	Molecular Determinants of Radiation Response in Non–Small Cell Lung Cancer. Seminars in Radiation Oncology, 2015, 25, 67-77.	1.0	8
155	To SABR or Not to SABR? Indications and Contraindications for Stereotactic Ablative Radiotherapy in the Treatment of Early-Stage, Oligometastatic, or Oligoprogressive Non–Small Cell Lung Cancer. Seminars in Radiation Oncology, 2015, 25, 78-86.	1.0	20
156	Noninvasive Genotyping and Assessment of Treatment Response in Diffuse Large B Cell Lymphoma. Blood, 2015, 126, 114-114.	0.6	10
157	Dynamic Noninvasive Genomic Monitoring for Outcome Prediction in Diffuse Large B-Cell Lymphoma. Blood, 2015, 126, 130-130.	0.6	9
158	Cancer Stem Cells and Tumor Radioresistance. , 2015, , 519-531.		0
159	Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2015, 33, 8539-8539.	0.8	0
160	Distinct early response dynamics of circulating tumor DNA and circulating tumor cells during therapy of B-cell NHL.. Journal of Clinical Oncology, 2015, 33, 8570-8570.	0.8	0
161	Illuminating Radiogenomic Characteristics of Glioblastoma Multiforme through Integration of MR Imaging, Messenger RNA Expression, and DNA Copy Number Variation. Radiology, 2014, 270, 1-2.	3.6	109
162	Feasibility and Potential Utility of Multicomponent Exhaled Breath Analysis for Predicting Development of Radiation Pneumonitis After Stereotactic Ablative Radiotherapy. Journal of Thoracic Oncology, 2014, 9, 957-964.	0.5	7

#	Article	IF	Citations
163	An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine, 2014, 20, 548-554.	15.2	1,771
164	Neuregulin Autocrine Signaling Promotes Self-Renewal of Breast Tumor-Initiating Cells by Triggering HER2/HER3 Activation. Cancer Research, 2014, 74, 341-352.	0.4	30
165	FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution. Bioinformatics, 2014, 30, 3390-3393.	1.8	212
166	Lung Volume Reduction After Stereotactic Ablative Radiation Therapy of Lung Tumors: Potential Application to Emphysema. International Journal of Radiation Oncology Biology Physics, 2014, 90, 216-223.	0.4	5
167	Galectin-1 Mediates Radiation-Related Lymphopenia and Attenuates NSCLC Radiation Response. Clinical Cancer Research, 2014, 20, 5558-5569.	3.2	64
168	Pulmonary Ventilation Imaging Based on 4-Dimensional Computed Tomography: Comparison With Pulmonary Function Tests andÂSPECT Ventilation Images. International Journal of Radiation Oncology Biology Physics, 2014, 90, 414-422.	0.4	81
169	Targeting Unique Metabolic Properties of Breast Tumor Initiating Cells. Stem Cells, 2014, 32, 1734-1745.	1.4	97
170	Vagal and recurrent laryngeal neuropathy following stereotactic ablative radiation therapy in the chest. Practical Radiation Oncology, 2014, 4, 272-278.	1.1	15
171	A Population-Based Comparative Effectiveness Study of Radiation Therapy Techniques in Stage III Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 88, 872-884.	0.4	69
172	Imaging Features Associated With Disease Progression After Stereotactic Ablative Radiotherapy for Stage I Nonâ€"Small-Cell Lung Cancer. Clinical Lung Cancer, 2014, 15, 294-301.e3.	1.1	25
173	The effect of arm position on the dosimetry of thoracic stereotactic ablative radiation therapy using volumetric modulated arc therapy. Practical Radiation Oncology, 2014, 4, 192-197.	1.1	3
174	Overcoming Radioresistance of Lung Cancer Stem Cells. Stem Cells and Cancer Stem Cells, 2014, , 117-127.	0.1	2
175	Stem Cells, Cell Differentiation, and Cancer. , 2014, , 98-107.e3.		1
176	Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. Journal of Clinical Investigation, 2014, 124, 553-563.	3.9	53
177	Neurotrophic factor GDNF promotes survival of salivary stem cells. Journal of Clinical Investigation, 2014, 124, 3364-3377.	3.9	96
178	Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL.. Journal of Clinical Oncology, 2014, 32, 8504-8504.	0.8	0
179	Noninvasive and ultrasensitive quantitation of circulating tumor DNA by hybrid capture and deep sequencing.. Journal of Clinical Oncology, 2014, 32, 11016-11016.	0.8	0
180	Clinical impact of dose overestimation by effective path length calculation in stereotactic ablative radiation therapy of lung tumors. Practical Radiation Oncology, 2013, 3, 294-300.	1.1	19

#	Article	IF	Citations
181	Clinical Implementation of Intrafraction Cone Beam Computed Tomography Imaging During Lung Tumor Stereotactic Ablative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 87, 917-923.	0.4	32
182	The Optimal Use of Radiotherapy in Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 107-114.	2.3	1
183	4D CT lung ventilation images are affected by the 4D CT sorting method. Medical Physics, 2013, 40, 101907.	1.6	52
184	Migration of implanted markers for image‐guided lung tumor stereotactic ablative radiotherapy. Journal of Applied Clinical Medical Physics, 2013, 14, 77-89.	0.8	19
185	Stereotactic Ablative Radiotherapy for Reirradiation of Locally Recurrent Lung Tumors. Journal of Thoracic Oncology, 2012, 7, 1462-1465.	0.5	78
186	Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors. International Journal of Radiation Oncology Biology Physics, 2012, 84, 231-237.	0.4	66
187	Intrafraction Verification of Gated RapidArc by Using Beam-Level Kilovoltage X-Ray Images. International Journal of Radiation Oncology Biology Physics, 2012, 83, e709-e715.	0.4	27
188	Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy. Lung Cancer, 2012, 78, 219-224.	0.9	46
189	Mechanisms of Radioresistance in Cancer Stem Cells. , 2011, , 345-360.		0
190	In Reply to Song etÂal.. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1194.	0.4	0
191	38, 2424-2429.	1.6	24
192	Tumor Volume as a Potential Imaging-Based Risk-Stratification Factor in Trimodality Therapy for Locally Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 920-926.	0.5	26
193	High Retention and Safety of Percutaneously Implanted Endovascular Embolization Coils as Fiducial Markers for Image-Guided Stereotactic Ablative Radiotherapy of Pulmonary Tumors. International Journal of Radiation Oncology Biology Physics, 2011, 81, 85-90.	0.4	38
194	In Reply to Drs. Koch and Evans. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1605.	0.4	0
195	What the Diagnostic Radiologist Needs to Know about Radiation Oncology. Radiology, 2011, 261, 30-44.	3.6	19
196	Stereotactic Ablative Radiotherapy Should Be Combined With a Hypoxic Cell Radiosensitizer. International Journal of Radiation Oncology Biology Physics, 2010, 78, 323-327.	0.4	131
197	The Myc Connection: ES Cells and Cancer. Cell, 2010, 143, 184-186.	13.5	18
198	Metastatic Cancer Stem Cells: An Opportunity for Improving Cancer Treatment?. Cell Stem Cell, 2010, 6, 502-503.	5.2	17

#	ARTICLE	IF	CITATIONS
199	Therapeutic Implications of the Cancer Stem Cell Hypothesis. Seminars in Radiation Oncology, 2009, 19, 78-86.	1.0	130
200	Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature, 2009, 458, 780-783.	13.7	2,232
201	Downregulation of miRNA-200c Links Breast Cancer Stem Cells with Normal Stem Cells. Cell, 2009, 138, 592-603.	13.5	1,130
202	Type I collagen is overexpressed in medulloblastoma as a component of tumor microenvironment. Journal of Neuro-Oncology, 2008, 86, 133-141.	1.4	51
203	Isolation and Molecular Characterization of Cancer Stem Cells in MMTV-*Wnt-1* Murine Breast Tumors. Stem Cells, 2008, 26, 364-371.	1.4	262
204	Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5213-5218.	3.3	408
205	Cancer Stem Cells and Radiotherapy: New Insights Into Tumor Radioresistance. Journal of the National Cancer Institute, 2006, 98, 1755-1757.	3.0	207
206	Cell-type specific gene expression profiles of leukocytes in human peripheral blood. BMC Genomics, 2006, 7, 115.	1.2	275
207	Genome-Scale Identification of Membrane-Associated Human mRNAs. PLoS Genetics, 2006, 2, e11.	1.5	84
208	Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 5814-5819.	3.3	445
209	Differential gene expression in anatomical compartments of the human eye. Genome Biology, 2005, 6, R74.	13.9	55
210	A method for detecting and correcting feature misidentification on expression microarrays. BMC Genomics, 2004, 5, 64.	1.2	11
211	Individuality and variation in gene expression patterns in human blood. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 1896-1901.	3.3	723
212	SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data. Nucleic Acids Research, 2003, 31, 219-223.	6.5	376
213	Gene Expression Patterns in Ovarian Carcinomas. Molecular Biology of the Cell, 2003, 14, 4376-4386.	0.9	302
214	T Cell Receptor-Independent Basal Signaling via Erk and Abl Kinases Suppresses RAG Gene Expression. PLoS Biology, 2003, 1, e53.	2.6	88
215	Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 972-977.	3.3	371
216	Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 8886-8891.	3.3	204

#	Article	IF	Citations
217	Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11796-11801.	3.3	300
218	In Vivo Regulation of Human Skeletal Muscle Gene Expression by Thyroid Hormone. Genome Research, 2002, 12, 281-291.	2.4	143
219	Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biology, 2002, 3, research0032.1.	13.9	158
220	Transcriptional response of human mast cells stimulated via the Fc(epsilon)RI and identification of mast cells as a source of IL-11. BMC Immunology, 2002, 3, 5.	0.9	56
221	Comparing functional genomic datasets: lessons from DNA microarray analyses of host–pathogen interactions. Current Opinion in Microbiology, 2001, 4, 95-101.	2.3	59
222	Large-scale identification of secreted and membrane-associated gene products using DNA microarrays. Nature Genetics, 2000, 25, 58-62.	9.4	241
223	Biochemical Interactions Integrating Itk with the T Cell Receptor-initiated Signaling Cascade. Journal of Biological Chemistry, 2000, 275, 2219-2230.	1.6	244
224	Degradation of Proteins from the ER of S. cerevisiae Requires an Intact Unfolded Protein Response Pathway. Molecular Cell, 2000, 5, 729-735.	4.5	171